Skip to content

Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy

Verify the Safety and Effectiveness of the Cerclage Pessary in the Prevention and Treatment of High-risk Preterm Pregnancy

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03637062
Enrollment
300
Registered
2018-08-17
Start date
2024-12-01
Completion date
2026-12-01
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Risk Pregnancy

Brief summary

Verify the safety and effectiveness of the cerclage pessary in the prevention and treatment of high-risk preterm pregnancy.

Detailed description

Prospective Open-label Multicentre Randomized Controlled Trial. high-risk preterm pregnancy is that there are at least one history of spontaneous preterm birth and/or late abortion before 34+0 weeks, for high-risk pregnant women that meet the inclusion criteria, the early treatment with cerclage pessary at 12-18weeks compare with routine treatment. The patients will be informed of the intended therapeutic effect and possible side effects. If they agree and after obtaining their informed consent, they will be randomized to test group (cerclage pessary group) and control group (Utrogestan group).

Interventions

DRUGProgesterone

progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.

DEVICEpessary

pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.

Sponsors

QH Medical Technology Ltd.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open Multicentre Randomized Controlled Trial, in parallel groups, based on treatment with progesterone comparing the placement of a prophylactic cervical pessary with usual management in singleton pregnancies at high-risk of PTB due to a history of at least one previous preterm delivery and/or a history of late abortion

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women with a pregnancy and a history of at least one spontaneous preterm birth before 34+0 weeks and/or a history of late abortion * 12+0 -18+0 weeks of gestation * Minimal age of 18 years * Informed consent signature

Exclusion criteria

* The previous preterm delivery is iatrogenic proterm labor * Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap) * The pregnant woman with severe cervical erosion, cervical polyp, hemorrhage and the doctors think she could not use cerclage pessary * The pregnant woman with uterine cervicitis * The pregnant woman that has been confirmed premature birth * Cerclage prior to randomisation * Cerclage prior to randomisation * Placenta previa totalis * Active vaginal bleeding at the moment of randomization * Spontaneous rupture of membranes at the time of randomization * Silicone allergy * Painful regular uterine contractions * The pregnant woman have the indication of operation cervical cerclage * Current participation in other RCT

Design outcomes

Primary

MeasureTime frameDescription
Child's birth and survival(rate)34+0 weeksChild's birth and survival

Secondary

MeasureTime frameDescription
Birth weight of Offspring(g)before 37+0 weeksmedian weight (g) of the newborns at birth
Fetal or neonatal death (rate)before 37+0 weeksrate of intrauterine demise or neonatal death during the first 24 hours
Neonatal morbidity (rate)before 37+0 weeksrate of major adverse neonatal outcomes before discharge from the hospital: * Intraventricular Haemorrhage (IVH): grades III-IV * Retinopathy of prematurity * Respiratory Distress Syndrome (RDS): grades II-IV * Need for ventilation \> 72 h * Necrotising enterocolitis * Proven or suspected sepsis, antibiotics (\>5 days) * Need (Duration in days) for neonatal special care (NICU)
Harm from intervention(Case Report Form)before 37+0 weeksHarm from intervention
Maternal death(rate)before 37+0 weeksMaternal death
Time to birth of Offspring(gestational weeks)before 37+0 weeks* Preterm birth before 37 weeks: rate of delivery before 36+6 weeks * Preterm birth before 34 weeks: rate of delivery before 33+6 weeks * Preterm birth before 32 weeks: rate of delivery before 31+6 weeks * Preterm birth before 30 weeks: rate of delivery before 29+6 weeks * Preterm birth before 28 weeks: rate of delivery before 27+6 weeks
Physical or psychological intolerance to pessary for mother(number of cases)before 37+0 weeksdiscomfort or pain due to the pessary that makes daily life uncomfortable
Rupture of membranes before 32 weeks for mother(rate)before 37+0 weeksrate of rupture of amniotic membranes before 31+6 weeks
inflammation 3rd stage of chorioamnionitis(rate)before 37+0 weeksinflammation 3rd stage of chorioamnionitis
Hospitalisation for threatened preterm labour before 32 weeks(Case Report Form)before 37+0 weeksrequirement of hospitalisation due to preterm contractions that need medical treatment to try to stop them before 31+6 weeks * Mean hospital stay duration: number of days of admittance at the hospital * Use of tocolytic treatment: Type of tocolytic, days of treatment, dose
Significant maternal adverse events (rate)before 37+0 weeks* Heavy bleeding: bleeding that requires a medical intervention * Cervical tear: cervical rupture due to the pessary placement * Uterine rupture: rupture of the uterus due to contractions or surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026